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Background: Tumor epigenetic defects are of increasing relevance to clinical practice, 
because they are ‘druggable’ targets for cancer therapy using chromatin-remodeling 
agents (CRAs). New evidences highlight the importance of the microenvironment 
on the epigenome regulation and the need to use culture models able to preserve 
tissue morphology, to better understand the action of CRAs. Methods & methods: We 
studied the epigenetic response induced by culturing and CRAs in a preclinical model, 
preserving ex vivo the original tissue microenvironment and morphology, assessing 
different epigenetic signatures. Our overall findings suggest that culturing and 
CRAs cause heterogeneous effects on the genes methylation; CRAs affect the global 
DNA methylation and can trigger an active DNA demethylation; the culture induces 
alterations in the histone deacetylase expression. Conclusion: Despite the limited 
number of cases, these findings can be considered a proof of concept of the possibility 
to test CRAs epigenetic effects on ex vivo tissues maintained in their native tissue 
architecture.
First draft submitted: 17 August 2015; Accepted for publication: 13 November 2015; 
Published online: 7 March 2016
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Epigenetics refers to variations of gene expres-
sion without any change in the DNA sequence, 
including the addition of chemical groups that 
covalently bind to the DNA and the histones. 
The most important changes are the methyla-
tion of cytosine, methylation, acetylation and 
ubiquitination of the histone tails. The epi-
genetic modifications are heritable during cell 
divisions and primarily regulate the physical 
DNA accessibility to the molecular complexes 
designate to transcription, controlling gene 
expression [1–3].
The alterations of the epigenetic pathways 
are very frequently present in cancer and now 
considered as hallmarks of tumorigenesis, 
together with genetic/genomic variations. 
The knowledge of the epigenetic changes is 
of increasing relevance in clinical practice 
focused to discover novel therapeutic targets, 
such as the epigenetic regulatory enzymes, 
‘druggable’ targets for cancer therapy [4,5].
In the past few years, several drugs with epi-
genetic activity have received approval for the 
treatment of cancer patients, the ‘epigenetic 
cancer therapy’ [6–8], leading to an increased 
interest on their modes of action. The main 
‘epigenetic drug’ classes, the HDAC inhibi-
tors and the DNMT inhibitors, have proven 
chromatin remodeling properties, however, 
they show substantial limitations in their epi-
genetic specificity [5–8] and, moreover, for a 
number of drugs, not all the molecular targets 
are yet known. In addition, an increasing body 
of evidence highlights that, despite the proven 
clinical benefit of the epigenetic drugs, a direct 
link between the clinical response and the spe-
cific epigenetic modification induced by the 
treatment has not yet been fully elucidated [4].
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The microenvironment plays a significant role in 
human cancer progression although its influence on 
tumor epigenetics remains unclear [9,10]. There are 
only two reports on epigenetic changes in 3D cul-
ture models [11,12] and no studies have yet reported on 
the chromatin remodeling agents (CRAs) effects on 
ex vivo structurally intact tissues. DesRochers et al. [11] 
documented, in 3D tissue cultures, that the epigenetic 
regulation of the E-cadherin is dynamic and sensitive 
to the induction of complex homotypic cell–cell inter-
actions. Moreover, Amatangelo et al. [12], investigat-
ing on 2D and 3D human epithelial ovarian cancer 
cultures the effect of a specific inhibitor of the histone 
methyltransferase EZH2, observed inhibition of cell 
growth, invasion and apoptosis induction in the 3D 
culture only. Both studies highlight the importance of 
the microenvironment and 3D architecture on tumor 
epigenetic modifications.
The importance of the microenvironment in tumor 
biology suggests the need to use culture models able 
to preserve the complex tissue architecture to better 
understand the mode of action of CRAs.
We investigated, in a preclinical model characterized 
by organotypic cultures [13,14], the epigenetic response 
induced by culturing, HDAC inhibitor Trichostatin 
A (TSA) and DNMT inhibitor 5-aza-2’deoxycytidine 
(5-Aza-CdR). The organotypic culture preserves 
ex vivo the original tissue microenvironment and the 
morphology, cell viability, 3D architecture and tumor 
heterogeneity. Recently, this model has been indepen-
dently validated to predict the clinical response to anti-
cancer drugs [15]. The epigenetic response to culture 
and CRAs was evaluated in cells from non-neoplastic 
and neoplastic tissues maintaining their original struc-
ture. In organotypic cultures obtained from lung sur-
gery, we assessed: the global DNA methylation and 
hydroxymethylation levels; the methylation profile of 
‘long interspersed nuclear elements’ LINE1 and the 
methylation status of a panel of genes with tissue-spe-
cific expression or with tumor suppressor activity; the 
expression pattern of several HDACs.
Materials & methods
Samples
Fresh tumor (n = 12) and adjacent nontumor (n = 3) 
lung tissues were recovered immediately after surgi-
cal resection at the Division of Pathology, Fondazione 
IRCCS Ca’ Granda Ospedale Maggiore Policlinico, 
Milano, Italy. Tumor samples were composed of an 
epithelial neoplastic component (adenocarcinoma 
n = 9; metastatic colonic adenocarcinoma n = 1; squa-
mous cell carcinoma n = 2) and a supporting stroma 
which was made up of vessels, fibroblasts and inflam-
matory cells. Adenocarcinomas were subtyped accord-
ing to 2014 WHO classification. Clinical pathological 
features are shown in Table 1.
The patients did not receive chemotherapy and/or 
radiotherapy before surgery. Informed consent was 
obtained from all patients and approved by Institu-
tional Ethical Committee of the IRCCS Fondazione 
Ospedale Maggiore Policlinico (Milan, Italy).
Organotypic tissue slices preparation, culturing 
& treatments
In order to prepare the organotypic tissue cultures, 
fresh tissue samples were immediately cut into serial 
thin slices (400 μm) using a vibratome VT1200 (Leica 
Microsystems, Wetzlar, Germany). The tissue slices 
were cultured as previously described by our group [13]. 
Tissue slices were treated with 330, 660 nM TSA 
(Sigma Aldrich, St. Louis, MO, USA) for 24 h or with 
100, 250, 500 μM 5-Aza-CdR (Sigma Aldrich, St. 
Louis, MO, USA) for 96 h. 5-Aza-CdR was dissolved 
at the concentration of 50 mM in 0.45% NaCl con-
taining 10 mM sodium phosphate (pH 6.8), while for 
TSA a 3.30 mM solution in absolute ethanol was pre-
pared. Tissue slices treated with vehicle were included 
as control. At the each time point (T0, after 24 h or 
96 h of culture and treatment), tissue slices were col-
lected and formalin-fixed and paraffin-embedded 
(FFPE) for further analyses.
Morphological & immunohistochemical 
analysis
All FFPE samples were analyzed for morphologic integ-
rity assessment by Hematoxylin and Eosin (H&E) 
staining. Immunohistochemistry (IHC) analysis was 
performed using antibodies against 5-methylcytosine 
(5-mC, 1:400; ab10805; Abcam, Cambridge, UK), 
HDAC1 (1:1000; NBP1–78101; Novus Biologicals, 
Littleton, CO, USA), HDAC2 (1:1000; NBP2–16790; 
Novus Biologicals), HDAC3 (1:1000; NB110–57033; 
Novus Biologicals), HDAC4 (1:400; NBP2–16793; 
Novus Biologicals), HDAC6 (1:200; NBP2–03269; 
Novus Biologicals).
Apoptosis was analyzed using anticleaved caspase-3 
(Casp3) antibody (1:4000; #9661; Cell Signaling, 
Boston, MA, USA). The Casp3 score was calculated 
as the percentage of positive cells in the sample. A 
two-score system for the percentage of positive cells 
and the intensity of staining was used to quantify the 
reactivity of 5-mC and HDACs levels. The intensity 
of staining was expressed in a scale of 0 (absent stain-
ing) to 3 (strong staining). Two investigators indepen-
dently examined all slides and, when discrepancies 
occurred, the cases were reviewed until a consensus was 
reached. Representative images were obtained using 
an LMD108 system (Leica Microsystems, Wetzlar, 
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Germany). For each IHC analysis, we included two 
negative and one positive controls: a tissue slide with 
only the secondary antibody and one with only the pri-
mary antibody (negative controls) and, in agreement 
with manufacturer’s instruction, a tissue slide positive 
for the analyzed protein (positive control).
DNA isolation, conversion & pyrosequencing
Genomic DNA was purified from five 10 μm thin 
FFPE slices using the QIAamp DNA Mini Kit (Qia-
gen, Limburg, The Netherlands), according to the 
supplier’s protocol. Sodium bisulphite conversion of 
DNA (400 ng) was performed using the EZ DNA 
Methylation-Direct™ Kit (Zymo Research Corpora-
tion, Orange, CA, USA). PCR of the promoters of the 
following genes: CYP1A1, MGMT, RARβ, CDH13, 
RASSF1A, ESR1 and DAPK1  were performed using 
100–170 ng of bisulphite-treated DNA and 10 pmol 
of forward and reverse primers. Pyrosequencing assays 
were carried out using the Pyro Mark ID instrument 
(Qiagen, Limburg, The Netherlands) as previously 
described [16,17]. Raw data were analyzed using the 
Q-CpG software v1.0.11 (Biotage, Uppsala, Sweden), 
which calculates the ratio of converted C (T) to uncon-
verted C at each CpG site, giving the percentage of 
methylation. Primer sequences and genomic positions 
are provided in Table 2.
PyroMark® Q96 CpG LINE-1 kit (Qiagen, Lim-
burg, The Netherlands) was used to analyze the LINE1 
retrotransposable elements methylation levels, accord-
ing to manufacturer’s protocol. Specifically, the meth-
ylation levels were determined by the quantification of 
methylation of four CpG sites in position 331–305 of 
LINE1 (Gene Bank accession number X58075).
DNA slot blotting
For each sample, 500 and 300 ng of DNA were analyzed 
to evaluate the 5-hydroxymethylcytosine (5-hmC) and 
5-mC, respectively. DNA was added to the denatur-
ation buffer (0.4 mM NaOH, 10 mM EDTA) in a final 
volume of 200 μl and denatured for 10 min at 100° C. 
Samples were rapidly chilled for 5 min on ice and then 
applied to a positively charged nylon membrane (Amer-
sham Hybond–N+, GE Healthcare, Little Chalfont, 
UK) using a 24-well slot blot vacuum manifold (Hybri-
slot manifold, Bethesda Research Laboratories, USA). 
The membrane was twice washed in 2× SSC buffer 
and air-dried. Membranes were probed with monoclo-
nal antibodies specific to 5-mC (1:500) and to 5-hmC 
(1:2000) (Monoclonal antibody hydroxymethyl and 
methylcytosine detection kit BI-KMCY-0050, Euro-
gentec Kaneka, Osaka, Japan). As loading control, the 
same membranes were probed with a rabbit polyclonal 
antibody (1:1000) raised against single-stranded DNA 
(α-ssDNA, Demeditec Diagnostics, Kiel-Wellsee, Ger-
many). Subsequently, membranes were blotted with 
either a mouse (α-5mC and α-5hmC membranes) or 
a rabbit (α-ssDNA membranes) IgG antibody (1:5000, 
Santa Cruz Biotechnology, Dallas, Texas, USA) conju-
gated to horseradish peroxidase. Following treatment 
Table 1. Clinical features of tumor samples.
Sample Sex Age Diagnosis Histological subtype Grading TNM
1K M 69 Lung ADCA Solid G3 pT1aN0
2K M 72 Colorectal cancer 
lung metastasis
 G2 –
3K F 62 Lung ADCA Solid G3 pT2bN0
4K M 65 Lung ADCA Acinar (50%) and 
lepidic growth (50%)
G2 pT1bN0
5K F 78 Lung ADCA Mucinous lepidic 
growth
G1 pT2aN0
6K M 68 Lung ADCA Acinar G2 pT1bN1M1
7K M 82 Lung SCC  G3 pT2aN0
8K F 74 Lung ADCA Acinar (30%) and 
lepidic growth (70%)
G1 pT1apN0
9K M 73 Lung ADCA Acinar (40%) and 
lepidic growth (60%)
G2 pT1aN0
10K F 59 Lung ADCA Acinar G3 pT1bN0
11K M 81 Lung SCC  G2 pT1bN1
12K F 56 Lung ADCA Acinar G2 pT2aN0
ADCA: Adenocarcinoma; F: Female; M: Male; SCC: Squamous cell carcinoma; TNM: Tumor node metastasis.
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Figure 1. Schematic overview of the experimental design. 
5-Aza-CdR: 5-aza-2’deoxycytidine; 5-mC: 5-methylcytosine; 5-hmC: 5-hydroxymethylcytosine; CV: Control vehicle; 
FFPE: Formalin-fixed, paraffin-embedded; TSA: Trichostatin A.
Tumor samples (K = 12)
Sectioning (Vibratome) of fresh samples
and plating into 6 well plate
T0 (fragment
not cultured) CV24h
HDAC levels (K = 9) – LINE1 and gene promoters methylation levels (K = 4)
– Apoptosis evaluation (K = 4)
– 5-mC and 5-hmC global levels (K = 7; N = 3)
– LINE1 and gene promoters methylation levels (K = 9; N = 3)
– Apoptosis evaluation (K = 7)
24h + TSA
FFPE
CV96h 96h + 5-Aza-CdR
Normal tissues (N = 3). Matched normal / tumor tissues (N / K = 2)
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with enhanced chemiluminescence substrate, mem-
branes were scanned on G:BOX Chemi XT4 (Syn-
gene, Cambridge, UK) imaging system. Spot intensity 
was quantified using GeneTools Gel Analysis software 
(Syngene). Intersample differences in global 5-hmC 
and 5-mC levels were calculated by densitometric anal-
ysis of slot blots. 5-hmC and 5-mC values were normal-
ized to the α-ssDNA loading control. Values are the 
means of two technical replicates. This method was 
previously described [18].
Statistical analysis
For the statistic evaluations, differences among sam-
ples were analyzed using the unpaired Student’s t-test 
and Prism 4.0 (GraphPad Inc, La Jolla, CA, USA) and 
the correlations were evaluated by the linear regres-
sion test. Statistical significance was assumed for a 
probability value (p) less than 0.05.
Results
The organotypic cultures were harvested after tis-
sue sectioning immediately after surgery. Briefly, the 
tumors were sliced by vibratome at 400 μm thick-
ness and cultured in 6-well plates for up to 96 h. 
The schematic overview of the experimental design is 
summarized in Figure 1.
Tissue composition and its variability in the serial 
slices were assessed histologically and epithelial/stroma 
percentages were scored in cultures, in relation to 
uncultured samples (control T0). In 12 out of 13 cases, 
the percentage of neoplastic (i.e., epithelial) cells dis-
played a maximum variation of 20% compared with 
T0. Only the case K3 showed, in part of the serial sec-
tions (T0 vs 24 h of culture), a larger variation. The 
validity of using a 20% cut off has been proposed 
and validated in previous studies applying molecular 
approaches [19].
The culture modifies the epigenetics of specific 
genes & of LINE1
Several epigenetic studies [20–28] carried out on primary 
or established cell lines, demonstrated that the proce-
dures of tissue dissociation (e.g., enzymatic treatment), 
the components of the culture medium (e.g., growth 
factors) as well as the ex vivo status can modify the 
epigenome.
To evaluate the effect of the in vitro condition on 
the epigenetics of cells maintained in their original 
organ architecture (organotypic culture), we quantita-
tively assessed the methylation of LINE1, which is an 
index of the global genome stability, and of a number 
of gene promoters, in organotypic cultures obtained 
from three normal (N), eight non-small-cell lung can-
cer (1,3–9 K) and one colorectal lung metastasis (2K) 
specimens (Table 1). Of these, two were normal-tumor 
pairs (6N-6K and 9N-9K).
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It is important to highlight that our model allows to 
analyze, for the first time, the real effect of the ex vivo 
culturing. Indeed, the epigenetic modifications in 
primary and established cell lines can be also due to 
additional effects such as the tissue dissociation and 
the cells selection.
For each sample, the methylation value represents the 
mean of at least two independent experiments with a 
standard deviation ≤3%. Given that, the pyrosequenc-
ing has an analytical sensitivity of 5% in detecting 
CpGs methylation [29], we considered as informative a 
methylation variation exceeding ±5%.
In a subset of cases, the overall methylation was also 
evaluated by IHC with 5-mC antibody.
In all experiments, we compared the T0 to the 
sample after 24 h of culture (CV24), using sequential 
tissue slices.
At 24 h of culture and in absence of drugs, among 
the cases with an appreciable methylation variation 
(seven out of twelve) we found an increase of LINE1 
methylation (range: +8/+25%) in six out of seven 
(Figure 2A & Supplementary Table 1).
This trend did not reflect the behavior of the gene 
promoters. Indeed, we observed that the promoter 
www.futuremedicine.com 347
Figure 2. Effect of culturing on the genes promoters and LINE1 methylation (see facing page). (A & B) Differences 
of methylation levels observed in LINE1 (A) and gene promoters (B) in neoplastic (1–9K) and non-neoplastic 
(6,9 and 13N) tissues obtained from lung surgery after 24 h (CV24) of organotypic culture. All CV24 samples 
were compared with uncultured tissues (T0). The boxes represent the differences of methylation expressed as 
percentages. The color scale is defined in the bottom. Methylation differences exceeding ±5% were considered 
informative. (C & D) 5-mC levels by immunohistochemistry observed at T0 and CV24. (C) Global methylation 
changes in CV24 compared with T0. Results were scored by multiplying the percentage of positive cells (0–100%) 
for the staining intensity (scale of 0-absent staining to 3-strong staining). Maximum value = 300. Bars represent 
mean ± standard error of the mean. (D) Representative images of four cases stained with H&E and a 5-mC antibody. 
Original magnification: ×200. 
5-mC: 5-methylcytosinel; H&E: Hematoxylin and Eosin.
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methylation of the investigated genes, both with 
tissue-specific expression (CYP1A1) and tumor sup-
pressor activity (MGMT, RARβ, CDH13, RASSF1A, 
ESR1 and DAPK1) variably changed (Figure 2B). In 
particular, two genes often showed changes exceeding 
±5% of the methylation range: CDH13 was frequently 
demethylated (six out of seven cases, range: -5/-13%), 
whereas CYP1A1 showed a heterogeneous response (six 
out of nine cases were demethylated, range: -6/-25%, 
whereas three displayed increase of methylation, range: 
+6/+39%) (Figure 2B & Supplementrary Table 1). How-
ever, the demethylated promoters at T0, rarely modi-
fied their methylation status (Supplementary Table 1).
We studied CYP1A1 methylation because the 
enhancer is methylated in normal lung and its demeth-
ylation can be associated with smoking habit [30,31].
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Figure 3. Apoptosis evaluation by cleaved casp3 assay. Percentage of cells positive to cleaved Casp 3 protein assay evaluated by 
immunohistochemistry in organotypic models at 24 h of culture (CV24) compared with uncultured tissues (T0) (A) and after treatment 
with TSA (B) compared with control vehicle (CV24). (C) Representative case (1K) stained with H&E and antibody against the cleaved 
Casp3. Original Magnification: ×40. (D) Cleaved protein positive cells (expressed as percentages) in tissue slices after 24 h of TSA 
treatment compared with T0 and CV24. Bars represent mean ± standard error of the mean. 
H&E: Hematoxylin and Eosin; TSA: Trichostatin A.
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In addition, we noted a different behavior of the tumor 
compared with the nontumor counterpart. The samples 
6K and 9K showed LINE1 (+8 and +23%, respectively), 
CYP1A1 (+9 and +6%, respectively) and CDH13 (-5% in 
9K) variations of methylation whereas, the correspond-
ing non-neoplastic tissues (6N and 9N), did not display 
methylation changes (Figure 2 & Supplementary Table 1). 
Despite the limited number of samples, we noted that, 
when cultured, normal tissues were epigenetically more 
stable compared with the cancer samples (Figure 2 
& Supplementary Table 1).
In seven cases (1–3K, 5–7K and 8K) we evaluated the 
global methylation by IHC with 5-mC antibody. Epi-
thelial tumor cells displayed methylation changes in five 
cases. In detail: 1K, 2K, 6K and 8K displayed increase 
and 3K decrease of the immunoreactivity (Figure 2C & D). 
Variations in LINE1s and/or promoters methylation were 
not correlated with the immunohistochemical changes.
Finally, using caspase 3 cleavage assay, we observed 
an induction of apoptosis in epithelial tumor cells after 
24 h of organotypic culture in three out of seven cases 
(Figure 3A, C & D). These data are in agreement with 
those obtained with in vitro primary or established cell 
lines cultures [32].
The epigenetic response to the chromatin 
remodeling agents
Several evidences demonstrated the epigenetic activity 
of the HDAC and DNMT inhibitors on primary or 
established cell lines [33–43]. In these culture models the 
link between the treatment and the epigenetic changes 
of specific targets is well documented, although this 
action is much less evident in clinical practice [4]. This 
is possibly ascribed to the relatively simple model rep-
resented by in vitro cell cultures compared with the 
complexity of the in vivo system. In order to evaluate 
the effects of CRAs on cells maintained in their tissue 
architecture, we analyzed, in our ex vivo model, the 
epigenetic changes of the LINE1 and the gene promot-
ers listed above after treatment with the HDAC inhibi-
tor TSA (cases 1–9K and 6N, 9N and 13N) and the 
DNMT inhibitor 5-Aza-CdR (cases 3K and 10–12K).
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Importantly, the demethylation of LINE1 and all 
the promoters analyzed in this study after treatment 
with CRAs, was previously described in tumor cell 
lines [34,35,37–43].
In the TSA experiments, we compared the untreated 
sample after 24 h of culture with the sample treated 
with TSA (330 and 660 nM) for 24 h, using sequential 
tissue sections.
After 24 h of culture in presence of TSA, we 
observed that the neoplastic and non-neoplastic 
samples showed an overall LINE1 demethylation 
(eight out of nine cases exceeding ±5% of the meth-
ylation variation, range: -10/-29%), as expected 
for HDAC inhibitor treatment, including cases in 
which the culture triggered an increased methylation 
(Figure 4A & Supplementary Table 2). This suggests a 
homogeneous effect of the drug on the repetitive DNA 
sequences in the organotypic culture model, irrespec-
tive to the changes induced by culture. In the same 
culture conditions, the gene promoters responded 
to TSA (330 or 660 nM) in a more variable manner 
(Figure 4B & Supplementary Table 2), showing demeth-
ylation for some promoters and increase of methyla-
tion for others (Figure 4B). Remarkably, we found an 
unexpected increase of methylation in some gene pro-
moters, in particular CYP1A1 (range: +7/+25%) and 
CDH13 (range: +6/+33%). This could be explained by 
the overall deregulation of cells epigenetics induced by 
TSA, which can result in down but also in upregulation 
of specific genes [44,45].
The study of the global methylation by IHC evi-
denced changes in all cases: 1K, 2K, 5K, 6K and 8K 
showed demethylation, whereas 3K and 7K displayed 
an increased methylation (Figure 4C & D). It is notable 
that in the cases 2K, 3K and 8K, the global methylation 
variations induced by culture were opposite, compared 
with that induced by TSA (Figure 2C & Figure 4C).
It was reported that CRAs lead to apoptosis in 
several types of cancer cell lines, including lung can-
cer [46,47]. Differently, in our experimental setting, 
we noticed variable levels of apoptosis irrespective of 
culturing conditions and TSA treatment (Figure 3). 
It is peculiar that, in cell maintained in their organ 
architecture, culture condition per se induced apoptosis 
powerfully then CRAs.
Finally, in cases 3K, 10–12K, we assessed the 
effect of DNMT inhibitor 5-Aza-CdR on the DNA 
methylation of LINE1, MGMT and RARβ promoters.
The 5-Aza-CdR demethylation activity depends on 
passive methylation loss and is not due to the direct 
inhibition of DNMT, and necessarily needs a longer 
treatment compared with that with the TSA (96 h vs 
24 h) [48]. Therefore, the organotypic culture is not the 
ideal model for investigating such a treatment.
Nevertheless, we analyzed serial tissue slices, compar-
ing the untreated sample after 96 h of culture with the 
sample treated with 5-Aza-CdR (100–250–500 μM) for 
96 h. Although after 96 h a significant amount of necrosis 
was generally present, we observed changes of methyla-
tion in both LINE1 and RARβ promoter (Figure 4E & F).
The culture conditions can remodel the HDACs 
expression status
To evaluate the possible correlation between the levels 
of HDACs and the epigenetic response to culture and 
TSA, we analyzed the expression status of the main 
TSA substrates: HDAC 1, 2, 3, 4 and 6. We evalu-
ated, by IHC analysis, the levels of the HDACs basal 
(T0) and after 24 h of culture in tumor epithelial and 
stromal cells. We have chosen to investigate HDAC 
expression by IHC, instead of the mRNA evaluation 
by RT-PCR, since IHC allowed us to distinguish the 
distribution of the HDAC enzymes within the tissue 
composition (epithelial vs stromal cells). We observed 
that the culture triggered a strong and sample-specific 
response of the HDACs expression. An overview of 
all cases, considering the entire panel of the analyzed 
HDACs, showed a reduction of the HDACs 2 (4K and 
6K), 3 (1K and 4–9K) and 6 (3K and 7–9K) in both 
tumor and stroma cells, and an increase of the HDAC 
4 (1–3K and 6–8K), whereas HDAC 1 was unchanged 
(Figure 5). In particular, cases 4–6, and 8K showed a 
strong reduction principally of the HDAC 2 and/or 3 
(Figure 5A). Interestingly, the case 2K, which had the 
higher response to culture and TSA treatment (based 
on variation of methylation in LINE1 and promoters), 
showed the most stable levels of HDACs expression 
after 24 h of culture (Figure 5). We observed a similar 
HDACs status at T0 and after 24 h of culture com-
paring tumor epithelial and stromal cells in almost all 
cases. We did not find significant correlation between 
the HDACs expression status and the epigenetic 
response (i.e., variation of methylation of LINE1 and 
promoters), probably due to the elevated variability of 
the sample response.
Culturing & chromatin remodeling treatment can 
increase the 5-hydroxymethylation global level
In order to better understand the effect of culture 
and chromatin remodeling treatment (TSA) on 
DNA methylation, we analyzed the global levels 
of 5-mC and 5-hmC. The 5-hmC is considered an 
intermediate of active DNA demethylation medi-
ated by TETs enzymes family [49–51]. However, it was 
recently reported that this modification could be also 
produced during passive demethylation [52].
We performed slot blot experiments using specific 
antibodies for 5-mC and 5-hmC, followed by densi-
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tometry quantification, on 10 tumor and 3 non-tumor 
samples (1–3, 5, 7, 10 and 11K, 6, 9 and 13N).
In all cases, the methylation and hydroxymeth-
ylation levels have been normalized and compared 
with the DNA amount. To assess the validity of 
our method, we applied the regression curve to 
the results obtained by the slot blot analysis with 
α-ssDNA, 5-mC and 5-hmC antibodies of a scalar 
dilutions of brain DNA and we found significant 
R2 values (5-mC R2 = 0.915 and 5-hmC R2 = 0.924, 
Supplementary Figure 1).
After 24 h of culture, in absence of the CRA, we 
observed a generalized increasing of the DNA meth-
ylation (eight out of ten cases) in both non-tumoral 
and tumor samples (Figure 6A). Differently, the levels 
of 5-hmC varied in a sample specific way, with an 
increase in six samples (2, 3, 7K and 6, 9 and 13N) 
and a decrease in the others (Figure 6B).
The treatment with TSA for 24 h modified the levels of 
both 5-mC and 5-hmC (Figure 6C & D). In particular, we 
observed a reduction of 5-mC in almost all the neoplastic 
and non-neoplastic samples. Interestingly, after the CRA 
treatment, the level of methylation in tumor samples was 
significantly lower than in non-tumoral samples (mean 
methylation 0.52 vs 1.06, respectively; p = 0.000067). 
Regarding the hydroxymethylation, we observed an 
appraisable increase of 5-hmC in three out of five tumors 
samples but not in non-neoplastic specimens.
Notably, we found a lower level of hydroxymeth-
ylation in tumor compared with nontumoral samples 
(mean hydroxymethylation 0.37 vs 1.35, respectively; 
p = 0.00001).
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Figure 4. Epigenetic response to chromatin remodeling agents in organotypic cultures (see facing page).  
(A & B) Differences of methylation levels observed in LINE1 (A) and gene promoters (B) in neoplastic (1–9K) and 
non-neoplastic (6, 9 and 13N) tissue slices after 24 h of TSA treatment. All TSA-treated samples were compared 
with the vehicle (CV24). The boxes represent the differences of methylation expressed as percentages. The 
color scale is defined in the bottom. Methylation differences exceeding ±5% were considered informative. 
(C & D) 5-mC levels by immunohistochemistry observed at T0 and after TSA treatment (330 and 660 nM). 
(C) Global methylation changes before and after TSA treatment. All data were scored by multiplying the 
percentage of positive cells (0–100%) for the staining intensity (scale of 0-absent staining to 3-strong staining). 
Maximum value = 300. Bars represent mean ± standard error of the mean. (D) Representative images of four 
cases, stained with H&E and a 5-mC antibody. Original magnification: ×200. (E & F) Differences of methylation 
levels expressed as percentages in LINE-1 and in RARβ and MGMT promoters observed after 96 h of culture 
(CV96) (E) and 96 h of treatment with 5-Aza-CdR (F). The cultured samples were compared with uncultured 
tissues (T0) (E) and the 5-Aza-CdR treated samples were compared with vehicle (CV96) (F). 
5-mC: 5-methylcytosine; H&E: Hematoxylin and Eosin; TSA: Trichostatin A.
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Figure 5. Effect of the culturing on the histone deacetylase expression(see facing page). (A) HDAC1–4 and 6 
expression levels observed by immunohistochemistry in uncultured tissues (T0, solid bars) and after 24 h of culture 
(CV24, dashed bars) in epithelial and stromal components of the tumor cases (1–9K). The values represented in the 
scale bars (maximum value = 300) are obtained by multiplying the percentage of positive cells (0–100%) for the 
staining intensity (scale of 0-absent staining to 3-strong staining). HDACs total loss was shown for each case. For 
each sample, the score value represents the mean of two independent experiments with a standard deviation ≤20. 
(B) Two representative cases at T0 and after 24 h culture stained for HDAC1, HDAC3 and HDAC6. 
Original magnification: ×200.
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Our overall results indicate a frequent (five out of 
eight cases) effect of the drug on DNA methylation 
and suggest that the culture and the TSA treatment 
can trigger an increment of 5-hmC that could be 
caused by active DNA demethylation.
Discussion
Differently from genetic alterations, epigenetic 
changes, although heritable, are reversible, thus 
presenting opportunities for therapeutic strategies 
designed to reverse transcriptional abnormalities 
involved in tumorigenesis. The main ‘epigenetic 
drugs,’ HDAC and DNMT inhibitors, have proven 
chromatin remodeling properties but show substan-
tial limitations in the epigenetic specificity and, to 
date, their mode of action in vivo is largely unclear.
Several epigenetic studies on primary or estab-
lished cell lines showed that culturing and CRAs 
treatments can modify the epigenome, commonly 
leading to a global demethylation [20–28,33–43]. How-
ever, cell lines models lose the tissue architecture, the 
tumor microenvironment and the spatial distribu-
tion of cancer and stromal cells within the tumor. 
Consequently, the influence of these crucial issues on 
the epigenetic response to environment changes and 
drug treatments is lost.
New evidences [11,12] highlighted the relevance of 
the microenvironment on the epigenetics and bring 
to light the need to use culturing models that are able 
to preserve the tissue morphology, to better under-
stand the effect of the culturing and CRAs on the 
epigenome.
We studied the epigenetic response induced by 
the culture and the treatments with TSA and 5-Aza-
CdR, in a preclinical model based on organotypic 
cultures from neoplastic and non-neoplastic speci-
mens, able to preserve the morphology of the tissue 
of origin, including the spatial distribution of cancer 
and stromal cells within the tumor.
It is important to note that the organotypic cul-
ture allowed us to analyze for the first time, the real 
effect of the ex vivo culturing, since the epigenetic 
variations in primary cell lines can be also due to 
other additional effects such as tissue dissociation 
and cells selection.
Comparing to other in vitro models, such as pri-
mary and established cell lines, in organotypic cul-
tures we found that culturing frequently induced an 
unexpected increase of the overall and LINE1 DNA 
methylation, whereas treatment with CRAs often led 
to a general DNA demethylation (IHC experiments), 
including LINE1. However, the culture and treat-
ment with CRAs may cause heterogeneous effects 
on gene promoters methylation, since the samples 
responded in a specific way, showing demethylation 
of some promoters and increased methylation of oth-
ers. Moreover, we explored the presence of the active 
demethylation, not previously investigated in 3D ex 
vivo condition, and we observed that culturing and 
TSA treatment trigger cytosine hydroxymethylation, 
that is an intermediate of the cytosine active demeth-
ylation [49–51]. However, we cannot exclude that the 
increase of the 5-hmC level can be also due to passive 
demethylation mechanisms [52].
Finally, we found that culturing can modify the 
HDACs expression pattern.
These overall results suggest an individual and 
case-specific epigenetic response of the samples, 
probably due to the original genetic and epigenetic 
status of each tissue and to heterogeneity in tumor 
composition. This individual response was also evi-
denced by the different ability of the tissues to trig-
ger the active DNA demethylation, highlighted by 
increased 5-hmC levels, and to modify the HDACs 
expression.
Notably, we found an increased methylation for 
some regions, also after treatment with TSA. Simi-
lar data, showing the downregulation of active 
genes after the CRAs treatment associated with 
epigenetic changes (enrichment of silenced chroma-
tin markers), have been already described. Rodri-
guez et al. [44] reported that upon 5-azacytidine and 
TSA treatment, transcriptional changes were accom-
panied by the loss of the CCCTC-binding factor at 
the boundaries of the different histone methylation 
domains, suggesting that drug treatment might also 
affect the locus structure and organization. Conse-
quently, expression domains are disrupted and the 
spreading of the silencing marks over the promoter 
regions of active genes of the domain can result in 
their transcriptional downregulation. These authors 
emphasized the importance of studying epigenetics 
in the context of chromatin domains rather than 
isolated genes, because transcriptional output for a 
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given gene after drug treatment depends not only on 
its basal chromatin modifications, but also on the 
chromatin signatures of the neighboring genes. This 
central concept is further integrated by our obser-
vations that the epigenetic profiles and the CRAs 
response are peculiar for each sample and probably 
influenced by the specific environmental context of 
each specimen.
Our overall findings on non-neoplastic tissues 
show a major epigenetic stability compared with 
tumor counterpart. Although more cases are needed 
to confirm these data, our observation is consistent 
with the new concept of the ‘epigenetic vulnerability’ 
of the tumor cells, based on the finding that epigen-
etic inhibitors cause a dramatic effect on malignant 
cells, whereas their normal counterparts remain gen-
erally unaltered. This evidence suggests that, in nor-
mal cells, the epigenetic regulators can function in 
a multilayered and redundant manner, allowing an 
‘epigenetic homeostasis.’ Differently, in cancer cells, 
a disturbance of the epigenetic balance, however 
slight, can be sufficient to result in a cell catastrophe, 
because the alteration in the expression of several 
cancer genes is often due to epigenetic defects [53].
Conclusion & future perspective
This study is the first report on the epigenetic effects 
of culturing and CRAs on normal and cancer cells 
maintained in their native tissue architecture.
We think that the different responses of the organo-
typic cultures to treatments and culturing could be 
related to the specific and unique genomic/epigenomic 
constitution of each sample that comprises the germ-
line and tumor profiles, and to the impact of the tissue 
microenvironment on tumor biology.
Our data, together with those of the literature, evi-
dence that the epigenetic landscape can be very sus-
ceptible to the environment conditions and can change 
very quickly. In our opinion, the organotypic cultures, 
based on their characteristics, can represent a preclini-
cal model more appropriate, comparing with cell lines, 
for epigenetic studies.
Executive summary
Background
•	 Alterations of epigenetic pathways are hallmarks of tumorigenesis, together with genetic and genomic 
variations.
•	 Tumor epigenetic defects are of increasing relevance to clinical practice, because they are important 
‘druggable’ targets for cancer therapy using chromatin-remodeling agents (CRAs).
•	 New evidences highlight the importance of the microenvironment in the epigenome regulation and stress the 
need to use culture models that are able to preserve tissue morphology to better understand the mode of 
action of CRAs.
Results
•	 We studied the epigenetic response induced by culture conditions and CRAs treatment, in a preclinical model 
of organotypic cultures, preserving ex vivo the original tissue microenvironment and morphology, from 
non-neoplastic and neoplastic specimens.
•	 We assessed different epigenetic signatures: the methylation profile of the LINE1; the methylation profile 
of a panel of tumor suppressor genes; the expression pattern of the histone deacetylase; the global DNA 
methylation and hydroxymethylation.
•	 Organotypic cultures highlighted important differences compared with other ex vivo models, such as primary 
and established cell lines.
•	 Culturing frequently induced an overall increase of LINE1 methylation, whereas CRAs caused LINE1 
demethylation. In addition, culture and CRAs caused heterogeneous effects on the genes methylation. The 
samples displayed an individual and specific response, showing demethylation of some promoters and an 
increased methylation of others.
•	 Our overall findings support that CRA drug treatments affect the global DNA methylation and can trigger an 
active DNA demethylation.
•	 Finally, we noted that the culture-induced alterations in the histone deacetylase expression pattern.
Conclusion
•	 We reported original data on the impact of the microenvironment and native tissue architecture on the 
epigenetic changes triggered by culturing and CRAs.
•	 Our overall data suggest that CRAs can work in a gene promoter specific manner.
•	 The variable responses of the organotypic cultures to treatments and culturing could be related to the specific 
and unique genomic/epigenomic constitution of each sample that comprises the germline and tumor profiles, 
and to the impact of the tissue microenvironment on tumor biology.
•	 Despite the limited number of cases, our findings can be considered a proof of concept of the possibility to 
test CRAs epigenetic effects on ex vivo tissues maintained in their native tissue architecture.
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Although our findings were obtained from a small 
number of cases, they can be considered as a proof of 
concept on the value to test CRAs epigenetic effects 
on ex vivo tissues. Therefore, the organotypic cul-
tures can be a useful and feasible approach to study 
the response of the tumor to epigenetic drugs.
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To view the supplementary data that accompany this paper 
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